
    
      A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety,
      PK and Antiviral Activity of Four Dosing Regimens of GW640385/rtv Therapy Compared to
      Open-label Current Protease Inhibitor (PI) Therapy in HIV-1, PI-Experienced Adults for 2 wks
      with Long-Term Evaluation (>48 wks) of Safety, PK and Antiviral Activity of Selected
      GW640385/rtv Dosing Regimen(s) vs. a RTV-boosted, PI Containing Regimen
    
  